Kuznicki Law is investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Prometheus will receive $200.00 in cash for each share of Prometheus that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Prometheus Biosciences, Inc. (NasdaqGS: RXDX) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.